

ЛИТЕРАТУРА

1. International Diabetes Federation. Idf Diabetes Atlas. Idf Diabetes Atlas. 2015 (7-th edition). doi:2-930229-80-2.
2. Алгоритмы специализированной медицинской помощи. Под ред. И.И. Дедова, М.В. Шестаковой. М., 2015.
3. Брай М. Сахарный диабет. Карманные рекомендации. Под ред. М.В. Шестаковой. М., 2013.
4. Standards of Medical Care in Diabetes. Diabetes Care, 2016, 39: 1.
5. Dedov I, Shestakova M, Benedetti MM, Simon D, Pakhomov I, Galstyan G. Prevalence of Type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res Clin Pract, March 2016. doi:10.1016/j.diabres.2016.02.010.
6. Федеральные клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом, 2014.
7. Клинические рекомендации по лечению морбидного ожирения у взрослых, 2014.
8. Национальное руководство по эндокринологии, 2013.
9. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Рекомендации ВНОК. М., 2009.
10. Сахарный диабет: многообразие клинических форм / под ред. И.И. Дедова, М.В. Шестаковой. М., 2016.
11. WHO Global status report on noncommunicable diseases, 2014.
12. Сусеков А.В. Рациональная фармакотерапия в кардиологии, 2011, 7(2): 231-240.
13. De Zeeuw D et al. Lancet Diabetes Endocrinol, 2015 Mar, 3(3): 181-90. doi: 10.1016/S2213-8587(14)70246-3.
14. Ryden L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration

with the European Association for the Study of Diabetes (EASD). *Eur Heart J*, 2013, 34(39): 3035-3087. doi: 10.1093/eurheartj/eh108.

15. Massimo F. Piepoli, Arno W. Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). *Eur Heart J*, 2016, 37(29): 2315-2381. doi: org/10.1093/eurheartj/ehw106.

16. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. *Lancet*, 2004, 364: 685-96.

17. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

18. Sever PS, Poulter NR, Dahlof B et al. Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA). *Am J Cardiol*, 2005, 96: 39F-44F.

19. Shepherd J, Barter P, Carmena R et al. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes. The Treating to New Targets (TNT) study. *Diabetes Care*, 2006, 29: 1220-6. Ford ES, Giles WH, Dietz.

20. Zeeuw D. de Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association – European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.

21. William T. Cefalu et al., *Diabetes Care, Journal of clinical and applied research and education*, January 2017, V. 40, Suppl.1

- 22.** Bangalore S et al. Diabetes mellitus as a compelling indication for use of renin-angiotensin system blockers: systematic review and meta-analysis of randomized trials. *BMJ*, 2016, 352.
- 23.** Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. *JAMA*, 2004, 292: 2217-26.
- 24.** Dahlof B, Sever PS, Poulter NR, for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*, 2005, 366: 895-906.
- 25.** Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the regression of atherosclerosis and the occurrence of clinical events. REVENT Investigators. *Circulation*, 2000, 102: 1503-10.
- 26.** Lee SA, Choi HM, Park HJ, Ko SK, Lee HY. Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. *Korean J InternMed*, 2014, 29(3): 315-24.
- 27.** Deanfield JE, Dertj JM, Lichtlen PR, Magnani B, Sellier P, Thaulow E. Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). *J Am CollCardiol.*, 1994, 15, 24(6): 1460-7.